|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology,rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically,it generates maximum revenue from the United States, followed by other markets. |
| 公司地址
| 210 Main Street West, Baudette, MN, USA, 56623 |
| 電話號碼
| +1 218 634-3500 |
| 傳真號碼
| +1 218 634-3540 |
| 公司網頁
| https://www.anipharmaceuticals.com |
| 員工數量
| 970 |
| Ms. Meredith W. Cook |
Senior Vice President, General Counsel and Corporate Secretary |
美元 408.70K |
10/04/2025 |
| Mr. Thomas Rowland |
Senior Vice President and Head, Established Brands |
-- |
10/04/2025 |
| Mr. Stephen P. Carey |
Senior Vice President, Finance, Principal Accounting Officer and Chief Financial Officer |
美元 509.86K |
27/02/2026 |
| Ms. Krista Davis |
Senior Vice President and Chief Human Resources Officer |
-- |
10/04/2025 |
| Mr. Ori Gutwerg |
Senior Vice President, Generics |
美元 463.06K |
10/04/2025 |
| Mr. Nikhil Lalwani |
Director, President and Chief Executive Officer |
美元 794.91K |
27/02/2026 |
| Mr. Christopher Mutz |
Senior Vice President and Head, Rare Diseases |
美元 447.86K |
10/04/2025 |
| Mr. Chad Gassert |
Senior Vice President, Corporate Development and Strategy |
-- |
10/04/2025 |
| Mr. Muthusamy Shanmugam |
Director and Head, Research and Development; Chief Operating Officer of New Jersey Operations |
-- |
27/02/2026 |
|
|
| Mr. Matthew J. Leonard |
Independent Director |
27/02/2026 |
| Mr. Thomas J. Haughey |
Chairman of the Board |
27/02/2026 |
| Mr. Patrick D. Walsh |
Director |
27/02/2026 |
| Dr. Renee P. Tannenbaum, D.Pharm. |
Independent Director |
27/02/2026 |
| Ms. Jeanne A. Thoma |
Independent Director |
27/02/2026 |
| Mr. Antonio R. Pera |
Independent Director |
27/02/2026 |
| Mr. Nikhil Lalwani |
Director, President and Chief Executive Officer |
27/02/2026 |
| Mr. Muthusamy Shanmugam |
Director and Head, Research and Development; Chief Operating Officer of New Jersey Operations |
27/02/2026 |
|
|
|
|
